EFFECT OF INHALED BUDESONIDE AND FORMOTEROL IN
TREATING MODERATE PERSISTENT CHILDREN ASTHMA
Xu LL, Ling XY, Hua XL
Union Hospital, Fujian Medical University,
Fuzhou, China
Objective: To evaluate the effects of adding formorterol to
Inhaled budesonide (BUD) in treating moderate persistent children asthma. Methods: Fifty patients with
moderate persistent asthma were randomly divided into two groups: inhaled
BUD 200μg/d qd plus formoterol tablets 4μg/kg.d
bid in groupsⅠand inhaled BUD 400μg/d
qd in groups II, treatment Continued for 3 months. The efficacy between
groups I and groups II were compared by symptoms scores, PEF% predicted and
daily PEF Variability (PEFV %).
Results: Symptoms scores (2.6±0.4
vs1.3±0.7 in group I, 2.7±0.3
vs 1.4±0.6 in groups II), and lung funtion (PEF % 70.2±4.8%
vs99.3±5.4 % in group I，71.6±4.5% vs 101.8±8.6
% in group II and PEFV% 34.1±3.4% vs
21.7±4.3% in group I，33.6±3.2% vs 22.0±.38%
in group II) had obvious difference between the patients before treatment
and those after treatment three months (P<0.01, repectively), the
improvements with formoterol were greater after treatment one month
(p<0.05). But the total effective rates in both groups were alike（100% vs 100%）after treatment 3 moths.
Conclusion: In symptomatic children with moderat asthma (especially for
nighttime symptoms) taking low to moderate doses of inhaled steroids, the
therapy of adding the long-acting β2-agonist may replace
that therapy of alone increasing corticosteroids dosage.